TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8722606

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol 17‐propionate cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol 17‐propionate ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.1% triamcinolone acetonide cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.1% triamcinolone acetonide ointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol 17‐propionate cream and ointment
Number of subjects: 0
Study: 1548248

Group type: EXPERIMENTAL
Intervention: Clonidine (approximately 0.005 mg/kg/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3935780

Group type: EXPERIMENTAL
Intervention: Short course of ampicillin
Number of subjects: 427

Group type: COMPARATOR
Intervention: Long course of ampicillin
Number of subjects: 427
Study: 31572243

Group type: EXPERIMENTAL
Intervention: Autonomy-enhancing treatment (AET), 15-session group-based
Number of subjects: 83

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: AET
Number of subjects: 83
Study: 29873089

Group type: EXPERIMENTAL
Intervention: Opioid misuse (defined as use of illicit or prescription opioids without a prescription or not as directed in the previous 6 months)
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Opioid misuse
Number of subjects: 1226
Study: 26852717

Group type: EXPERIMENTAL
Intervention: Itch Numeric Rating Scale (Itch NRS)
Number of subjects: 0
Study: 24647551

Group type: EXPERIMENTAL
Intervention: Video game training (Lumosity) - 20 sessions of 1 hour each
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no video game training)
Number of subjects: 27
Study: 21864204

Group type: EXPERIMENTAL
Intervention: Yohimbine challenge
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 20393454

Group type: EXPERIMENTAL
Intervention: CYP3A5 genotype-based tacrolimus dosing
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard daily regimen of tacrolimus
Number of subjects: 280
Study: 18592826

Group type: EXPERIMENTAL
Intervention: Extra-fine hydrofluoroalkane-beclomethasone (200 microg daily via an Autohaler)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Fluticasone dry powder inhaler (200 microg daily via a Diskus)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Extra-fine hydrofluoroalkane-beclomethasone
Number of subjects: 33
Study: 16117451

Group type: COMPARATOR
Intervention: Conventional dose of 300 IU/kg heparin for total body weight (TBW)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dose of 300 IU/kg heparin for calculated lean body mass (LBM)
Number of subjects: 27
Study: 12297361

Group type: EXPERIMENTAL
Intervention: Amoxycillin-clavulanate 2000/125 mg, twice daily
Number of subjects: 344

Group type: COMPARATOR
Intervention: Amoxycillin-clavulanate 1000/125 mg, three times daily
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 344
Study: 10726961

Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg bolus infusion)
Number of subjects: 16
Study: 9166360

Group type: EXPERIMENTAL
Intervention: Oxytocin administration to stimulate the pregnant uterus or ripen the cervix
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxytocin receptor antagonists
Number of subjects: 0
Study: 8445237

Group type: EXPERIMENTAL
Intervention: Malotilate (500 mg three times a day)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Malotilate
Number of subjects: 101
Study: 3088739

Group type: EXPERIMENTAL
Intervention: hydroflumethiazide 50 mg, Rauwolfia serpentina 50 mg and potassium chloride 625 mg (HFRK)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: clopamide 5 mg, reserpine 0.1 mg and dihydroergocristine 0.5 mg (CRE)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29752028

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO-OP) Approach
Number of subjects: 30
Study: 26894929

Group type: EXPERIMENTAL
Intervention: Risperidone treatment
Number of subjects: 114
Study: 24890996

Group type: EXPERIMENTAL
Intervention: Posterior stabilized (PS) polyethylene with a post
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cruciate substituting (CS) polyethylene without a post
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ball and socket joint
Number of subjects: 25
Study: 22682705

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 20194698

Group type: EXPERIMENTAL
Intervention: SP+AS+PQ (0.75 mg/kg of body weight)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441

Group type: COMPARATOR
Intervention: SP+AS
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: G6PD A-
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: G6PD A
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: G6PD B
Number of subjects: 441
Study: 18602045

Group type: EXPERIMENTAL
Intervention: Isobaric gasless laparoscopic‐assisted minilaparotomy (LA‐MLT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Isobaric gasless laparoscopic (LA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 16204902

Group type: EXPERIMENTAL
Intervention: Immediate anti-H. pylori treatment and oral ferrous sulfate
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Delayed anti-H. pylori treatment and oral ferrous sulfate
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Only oral ferrous sulfate (H. pylori negative patients)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Delayed anti-H. pylori treatment after one month
Number of subjects: 52
Study: 12432836

Group type: EXPERIMENTAL
Intervention: Epinephrine injection (1:10,000)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Epinephrine plus 2% polidocanol
Number of subjects: 500

Group type: COMPARATOR
Intervention: Epinephrine injection
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Epinephrine plus sclerosing agent
Number of subjects: 500
Study: 10489947

Group type: EXPERIMENTAL
Intervention: Azithromycin alone (n=233)
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Azithromycin plus rifabutin (n=224)
Number of subjects: 693

Group type: COMPARATOR
Intervention: Rifabutin alone (n=236)
Number of subjects: 693
Study: 8564089

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 5 mg/kg/d for 36 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 39
Study: 1827014

Group type: EXPERIMENTAL
Intervention: Isradipine after 4 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Isradipine after 12 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 30350117

Group type: EXPERIMENTAL
Intervention: Heating pad applied to the patient's sacrum during cystoscopy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group using a pad without heat
Number of subjects: 74
Study: 30814177

Group type: EXPERIMENTAL
Intervention: Primary debulking surgery
Number of subjects: 303

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Primary debulking surgery with no residual disease
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Primary debulking surgery with any residual disease
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Number of subjects: 303

Group type: COMPARATOR
Intervention: Intravenous chemotherapy
Number of subjects: 303
Study: 26340744

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (150 mg dabrafenib twice daily combined with 2 mg trametinib once daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Dabrafenib alone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (after adjustment for treatment switching)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Dabrafenib alone (before adjustment for treatment switching)
Number of subjects: 54
Study: 23579334

Group type: EXPERIMENTAL
Intervention: Aggressive rehabilitation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nonaggressive rehabilitation
Number of subjects: 36
Study: 21404197

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (hydration and analgesic on demand)
Number of subjects: 117
Study: 19564251

Group type: EXPERIMENTAL
Intervention: Materials Group (mailed educational materials)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Materials plus Personal Encounters Group (educational materials through interactions with community health workers)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: All children (combined data from both intervention groups)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nonrandomized contemporaneous control group
Number of subjects: 46
Study: 18245999

Group type: EXPERIMENTAL
Intervention: 0.5% Marcain (96 mL, 2 mL/h for 48 hours)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 0.5% Marcain
Number of subjects: 26
Study: 14985887

Group type: EXPERIMENTAL
Intervention: Post-gadolinium T1-weighted images with magnetization transfer (MT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Post-gadolinium T1-weighted images without magnetization transfer (MT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Subtraction images without magnetization transfer (MT)
Number of subjects: 31
Study: 11737399

Group type: EXPERIMENTAL
Intervention: ZDV + ddI
Number of subjects: 3207

Group type: EXPERIMENTAL
Intervention: ZDV + ddC
Number of subjects: 3207

Group type: COMPARATOR
Intervention: ZDV
Number of subjects: 3207
Study: 9605669

Group type: EXPERIMENTAL
Intervention: Oral glutamine (GLN) 0.5 g/kg/day during MTX neoadjuvant therapy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Methotrexate (MTX) 40 mg/m2 to 100 mg/m2 weekly for 3 weeks
Number of subjects: 9
Study: 8273984

Group type: EXPERIMENTAL
Intervention: 20 mg of omeprazole daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40 mg of omeprazole daily
Number of subjects: 10
Study: 2658396

Group type: EXPERIMENTAL
Intervention: telenzepine 3 mg once-daily at bedtime
Number of subjects: 314

Group type: COMPARATOR
Intervention: pirenzepine 50 mg two times daily
Number of subjects: 314
Study: 1124593

Group type: EXPERIMENTAL
Intervention: Commode use during defecation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Bedpan use during defecation
Number of subjects: 51
Study: 31678098

Group type: EXPERIMENTAL
Intervention: LOR-mod (moderate-dose Lorexys)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BUP (standard dose bupropion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LOR-low (subtherapeutic dose Lorexys)
Number of subjects: 0
Study: 27646264

Group type: EXPERIMENTAL
Intervention: High saturated fat meal
Number of subjects: 58

Group type: COMPARATOR
Intervention: High oleic sunflower oil meal
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: History of major depressive disorder (MDD)
Number of subjects: 58
Study: 25264599

Group type: EXPERIMENTAL
Intervention: Handling Our Problems Effectively (HOPE)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Forgiveness and Reconciliation through Experiencing Empathy (FREE)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Repeated assessment controls
Number of subjects: 145
Study: 22914115

Group type: EXPERIMENTAL
Intervention: Supraglottic airway devices (SAD)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (ETI)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mouth-to-mouth ventilation
Number of subjects: 50
Study: 20965577

Group type: EXPERIMENTAL
Intervention: RTL1000 (≤60 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 18317424

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Intervention with physician extender visit
Number of subjects: 140
Study: 17057563

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 13680036

Group type: EXPERIMENTAL
Intervention: L‐NMMA 0.3 mg/kg iv
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: L‐NMMA 1 mg/kg iv
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: L‐NMMA 3 mg/kg iv
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: L‐NMMA 6 mg/kg iv
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 6
Study: 10900778

Group type: EXPERIMENTAL
Intervention: Treatment with Support (school-based anti-bullying intervention with additional support)
Number of subjects: 1104

Group type: EXPERIMENTAL
Intervention: Treatment without Support (school-based anti-bullying programme without additional support)
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Control (schools that did not implement the anti-bullying programme)
Number of subjects: 1104
Study: 8737127

Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 1137

Group type: COMPARATOR
Intervention: Comparator antibacterial agents (amoxycillin/clavulanic acid, erythromycin, or amoxycillin)
Number of subjects: 1137
Study: 1570234

Group type: EXPERIMENTAL
Intervention: Low-dose Troleandomycin (TAO) therapy
Number of subjects: 11
Study: 4047798

Group type: EXPERIMENTAL
Intervention: Diet containing 25% of total calories as fat
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diet containing 50% of total calories as fat
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Preliminary observation period
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low fat intake (less than 27% of total calories)
Number of subjects: 18
Study: 29705444

Group type: EXPERIMENTAL
Intervention: Hand and foot surface stroke massage
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study: 27091601

Group type: EXPERIMENTAL
Intervention: Flavanol-rich dark chocolate (50g)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo chocolate (50g)
Number of subjects: 65
Study: 24949654

Group type: EXPERIMENTAL
Intervention: Once-daily insulin glulisine initiated at a fifth (20%) the dose of insulin glargine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Maximized dose of sitagliptin to 100 mg
Number of subjects: 62
Study: 23185923

Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine 25 microg combined with 0.5% hyperbaric bupivacaine 15 mg and fentanyl 25 microg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (0.5 ml) combined with 0.5% hyperbaric bupivacaine 15 mg and fentanyl 25 microg
Number of subjects: 60
Study: 20354436

Group type: EXPERIMENTAL
Intervention: Sheep sound played during anesthesia
Number of subjects: 300

Group type: COMPARATOR
Intervention: White noise played during anesthesia
Number of subjects: 300
Study: 18176737

Group type: EXPERIMENTAL
Intervention: Active transcranial magnetic stimulation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham transcranial magnetic stimulation
Number of subjects: 9
Study: 15923431

Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen (Irinotecan 180 mg/m² on day 1 with LV5FU2 regimen)
Number of subjects: 287
Study: 12842840

Group type: EXPERIMENTAL
Intervention: +1444TT homozygotes
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: CABG patients +1444TT homozygotes
Number of subjects: 443

Group type: COMPARATOR
Intervention: CABG patients
Number of subjects: 443
Study: 10832123

Group type: EXPERIMENTAL
Intervention: Group A (rt-PA 50 mg, 10 mg as a bolus plus 40 mg in 60 min)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group B (conventional therapy)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 90
Study: 8889351

Group type: EXPERIMENTAL
Intervention: Clinic-based screening
Number of subjects: 94

Group type: COMPARATOR
Intervention: Mass mailing campaigns
Number of subjects: 94

Group type: COMPARATOR
Intervention: Mass media campaigns
Number of subjects: 94

Group type: COMPARATOR
Intervention: Referrals by patients with end-stage renal disease
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Age-based randomization yields
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Overall prescreening
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Gender distribution
Number of subjects: 94
Study: 1639462

Group type: EXPERIMENTAL
Intervention: captopril (25 mg b.i.d.) for 4 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo for 4 days
Number of subjects: 46
Study: 6436868

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 1 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 2 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 4 g
Number of subjects: 6

Group type: COMPARATOR
Intervention: Diazepam 5 mg (Control)
Number of subjects: 6
Study: 31117149

Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus on-demand gastrocaine
Number of subjects: 132

Group type: COMPARATOR
Intervention: On-demand gastrocaine alone
Number of subjects: 132
Study: 28341106

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 0
Study: 25500787

Group type: EXPERIMENTAL
Intervention: MINT (phone-delivered Motivational Interviewing)
Number of subjects: 452

Group type: COMPARATOR
Intervention: DVD (educational video)
Number of subjects: 452
Study: 23039373

Group type: EXPERIMENTAL
Intervention: Volume guaranteed (VG) ventilation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional SIMV
Number of subjects: 72
Study: 20694577

Group type: EXPERIMENTAL
Intervention: Good Behavior Game (GBG) intervention
Number of subjects: 433

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 433
Study: 19337944

Group type: EXPERIMENTAL
Intervention: Juvederm ULTRA 3
Number of subjects: 126

Group type: COMPARATOR
Intervention: Restylane-Perlane
Number of subjects: 126
Study: 16456368

Group type: EXPERIMENTAL
Intervention: Nomogram protocol
Number of subjects: 153

Group type: COMPARATOR
Intervention: Chart protocol
Number of subjects: 153
Study: 15297583

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 99
Study: 11736725

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ulcer healing treatment followed by maintenance therapy
Number of subjects: 0
Study: 9622911

Group type: EXPERIMENTAL
Intervention: Rapid articulation process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retrieval of words from short-term memory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Profile of processing rates in the brain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age-related processing rates
Number of subjects: 0
Study: 7909049

Group type: EXPERIMENTAL
Intervention: Oral slow-release theophylline, 200 mg 12 hourly
Number of subjects: 19
Study: 2885367

Group type: EXPERIMENTAL
Intervention: Tiaspirone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard neuroleptics
Number of subjects: 9
Study: 30238557

Group type: EXPERIMENTAL
Intervention: Vitamin D3 5000 IU/day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 28042649

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (selenomethionine 83 mcg/day for four months)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (no selenium supplementation)
Number of subjects: 192
Study: 26121696

Group type: EXPERIMENTAL
Intervention: HEBI
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Plumpy'Nut
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (no RUTF)
Number of subjects: 160
Study: 25220321

Group type: EXPERIMENTAL
Intervention: Renal stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 22147129

Group type: EXPERIMENTAL
Intervention: Band Ligation (BL), n = 20
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate (CY), n = 18
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (diagnostic endoscopy), n = 20
Number of subjects: 58
Study: 19321012

Group type: EXPERIMENTAL
Intervention: Provision of single lens glasses, with counselling and advice about appropriate use
Number of subjects: 580

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 580
Study: 16849403

Group type: EXPERIMENTAL
Intervention: NBI-42902 (5 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: NBI-42902 (150 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: NBI-42902
Number of subjects: 56
Study: 12570823

Group type: EXPERIMENTAL
Intervention: Leukocytapheresis (LCAP) weekly for 5 weeks, then once every 4 weeks as maintenance therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: High dose prednisolone (h-PSL) 30-40 mg/day for moderately severe and 60-80 mg/day for severe patients, then gradually tapered
Number of subjects: 76
Study: 10863913

Group type: EXPERIMENTAL
Intervention: 3-D vision
Number of subjects: 3

Group type: COMPARATOR
Intervention: 2-D vision
Number of subjects: 3
Study: 9090733

Group type: EXPERIMENTAL
Intervention: Assertive community treatment only
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Assertive community treatment with community workers
Number of subjects: 165

Group type: COMPARATOR
Intervention: Broker case management
Number of subjects: 165
Study: 8477962

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (13 to 15 mg daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 3549909

Group type: EXPERIMENTAL
Intervention: Rowatinex
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28621011

Group type: EXPERIMENTAL
Intervention: Yoga intervention (8 weekly 75-min classes)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 26
Study: 27085288

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no LLLT)
Number of subjects: 30
Study: 24958663

Group type: EXPERIMENTAL
Intervention: Thin norm condition
Number of subjects: 146

Group type: COMPARATOR
Intervention: Heavy norm condition
Number of subjects: 146